Cambridge, MA-based biotech Achemix Corp. appointed Ken Bate to president and chief executive officer. Duncan Higgons, currently president and CEO, has accepted a position at another biotech, and will leave Achemix. Bate was previously president and CEO at NitroMed. Prior to that, he served as EVP, head of commercial operations and CFO at Millennium Pharmaceuticals.
Vertex Pharmaceuticals promoted Peter Mueller to EVP, global R&D chief and chief science officer. The promotion follows Freda Lewis-Hall’s move from Vertex to Pfizer. Mueller was previously Vertex’s EVP, drug innovation and realization, and chief scientific officer. Prior to Vertex, Mueller was SVP of R&D at Boehringer Ingelheim.
